Formoterol dry-powder inhalation - Novartis

Drug Profile

Formoterol dry-powder inhalation - Novartis

Alternative Names: Eformoterol dry-powder inhalation - Novartis; Foradil Aerolizer; Foradile Aerolizer; Formoterol fumarate dry-powder inhalation - Novartis

Latest Information Update: 28 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 28 May 2003 A pharmacoeconomic study has been added to the Respiratory Tract Disorders therapeutic trials section
  • 18 Mar 2003 Data presented at the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Asthma therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top